Senti Biosciences Holdings Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Senti Biosciences Holdings Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- SNTI
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001854270
Board of directors
-
Brenda Cooperstone · DirectorSince 2023
-
Donald F. Tang · DirectorSince 2024
- Since 2023
-
Feng Hsiung · DirectorSince 2025
-
Fran Schulz · DirectorSince 2024
-
James J. Collins · DirectorSince 2023
-
Omid Farokhzad · DirectorSince 2023
-
Susan D. Berland · DirectorSince 2023
-
Timothy K. Lu · Director · CEO and Interim PFO and PAOSince 2023
Chief executives
Timothy K. Lu
· CEO and President
Dates unknown
Board connections
4 of this board's directors also sit on 7 other boards.
- via James J. Collins
- via Brenda Cooperstone
- via Edward T. Mathers
- via Edward T. Mathers
- via Edward T. Mathers
- via Omid Farokhzad
- via Edward T. Mathers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2025 | Celadon Partners SPV 24 10% owner | Derivative conversion | +9,777,000 | — | — |
| Mar 10, 2025 | Florence Anthony A. Jr. 10% owner | Derivative conversion | +3,333,000 | — | — |
| Mar 10, 2025 | Bayer US Holding LP 10% owner | Derivative conversion | +2,222,000 | — | — |
| Mar 10, 2025 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Derivative conversion | +33,000 | $2.25 | $74,250 |
| Mar 7, 2025 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Grant or award | +78,363 | — | — |
| Mar 7, 2025 | Timothy K. Lu Director, Officer (CEO and Interim PFO and PAO) | Grant or award | +642,358 | — | — |
| Feb 6, 2025 | Timothy K. Lu Director, Officer (CEO) | Open-market sale | −545 | $4.36 | $2,376 |
| Feb 6, 2025 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Open-market sale | −182 | $4.37 | $795 |
| Feb 4, 2025 | Timothy K. Lu Director, Officer (CEO) | Open-market sale | −3,922 | $4.07 | $15,963 |
| Feb 4, 2025 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Open-market sale | −1,297 | $4.07 | $5,279 |
| Feb 1, 2024 | Rajangam Kanya Officer (Chief Medical & Devt. Officer) | Grant or award | +101,000 | — | — |
| Feb 1, 2024 | Timothy K. Lu Director, Officer (CEO and President) | Grant or award | +306,000 | — | — |
| Feb 1, 2024 | KNOBELMAN DEBORAH Officer (Chief Financial Officer), Head of Corporate Development | Grant or award | +101,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.